SNN · Smith & Nephew SNATS, Inc.
$27.50
-0.43% last session
End-of-day data · close of 2026-09-11
Market cap
$12B
Enterprise value
$62B
Trailing P/E
18.9
Forward P/E
11.5
Dividend yield
3.0%
Beta
0.68
Avg volume
2M
Employees
17K
Daily Change %
-0.43%
5 Days Change
-3.71%
10 Days Change
-3.34%
30 Days Change
-7.36%
60 Days Change
-9.45%
Month to Day Change
-4.04%
Year to Day Change
-13.98%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SNN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-31
Latest call per bank · past 12 months
JP Morgan
Neutral$0.00
-100.0% vs priceBarclays
Underweight$0.00
-100.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-31 | BTIG | Initiates | Neutral | $0.00 |
| 2026-08-06 | JP Morgan | Downgrade | Overweight → Neutral | $0.00 |
| 2026-08-05 | Barclays | Downgrade | Equal-Weight → Underweight | $0.00 |
| 2026-05-11 | Canaccord Genuity | Maintains | Hold | $32.00 → $30.00 |
| 2026-03-05 | Canaccord Genuity | Maintains | Hold | $34.00 → $35.00 |
| 2025-11-11 | Canaccord Genuity | Maintains | Hold | $36.00 → $34.00 |
| 2025-10-14 | Bernstein | Downgrade | Outperform → Market Perform | $0.00 → $37.50 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 31 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.2% below the 50-day MA ($29.96).
- Price vs 200-day MA: Trading 13.3% below the 200-day MA ($31.71).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.13) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($27.50).
SNN Price Chart
Loading chart for SNN…
Fundamentals
About Smith & Nephew SNATS, Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
More in Medical Devices
ABT
Abbott Laboratories
$179B -14.4% YTD
MDT
Medtronic plc.
$117B -2.7% YTD
SYK
Stryker Corporation
$104B -21.2% YTD
BSX
Boston Scientific Corporation
$62B -52.8% YTD
EW
Edwards Lifesciences Corporatio
$50B 1.1% YTD
DXCM
DexCom, Inc.
$32B 26.4% YTD
GEHC
GE HealthCare Technologies Inc.
$29B -20.4% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.